MarketFibrosis
Company Profile

Fibrosis

Fibrosis, also known as fibrotic scarring, is the development of fibrous connective tissue in response to an injury. Fibrosis can be a normal connective tissue deposition or excessive tissue deposition caused by a disease.

Physiology
Fibrosis is similar to the process of scarring, in that both involve stimulated fibroblasts laying down connective tissue, including collagen and glycosaminoglycans. The process is initiated when immune cells such as macrophages release soluble factors that stimulate fibroblasts. The most well characterized pro-fibrotic mediator is TGF beta, which is released by macrophages as well as any damaged tissue between surfaces called interstitium. Other soluble mediators of fibrosis include CTGF, platelet-derived growth factor (PDGF), and interleukin 10 (IL-10). These initiate signal transduction pathways such as the AKT/mTOR and SMAD pathways that ultimately lead to the proliferation and activation of fibroblasts, which deposit extracellular matrix into the surrounding connective tissue. This process of tissue repair is a complex one, with tight regulation of extracellular matrix (ECM) synthesis and degradation ensuring maintenance of normal tissue architecture. However, the entire process, although necessary, can lead to a progressive irreversible fibrotic response if tissue injury is severe or repetitive, or if the wound healing response itself becomes deregulated. ==Anatomical location==
Anatomical location
Fibrosis can occur in many tissues within the body, typically as a result of inflammation or damage. Common sites of fibrosis include the lungs, liver, kidneys, brain, and heart: Lungs FibrothoraxPulmonary fibrosisCystic fibrosisIdiopathic pulmonary fibrosis (idiopathic meaning 'of unknown cause') • Radiation-induced lung injury (following radiation therapies commonly used to treat cancer) Liver Bridging fibrosis – an advanced stage of liver fibrosis, seen in the progressive form of chronic liver diseases. The term bridging refers to the formation of a "bridge" by a band of mature and thick fibrous tissue from the portal area to the central vein. This form of fibrosis leads to the formation of pseudolobules. Long-term exposure to hepatotoxins, such as thioacetamide, carbon tetrachloride, and diethylnitrosamine, has been shown to cause bridging fibrosis in experimental animal models. • Senescence of hepatic stellate cells could prevent progression of liver fibrosis, although has not yet been implemented as a therapy due to risks associated with hepatic dysfunction. following a six-week course of thioacetamide. Sirius Red stain • Cirrhosis Kidney CYR61 induction of cellular senescence in the kidney has shown potential to limit renal fibrosis. Brain Glial scar Heart Myocardial fibrosis has two forms: • Interstitial fibrosis, described in cases of congestive heart failure and hypertension, and as part of normal cellular aging. • Replacement fibrosis, indicating tissue damage from previous myocardial infarction. • Crohn's disease (intestine) • Dupuytren's contracture (hands, fingers) • Keloid (skin) • Lipedema (fat cells, typically in lower limbs) • Mediastinal fibrosis (soft tissue of the mediastinum) • Myelofibrosis (bone marrow) • Myofibrosis (skeletal muscle) • Peyronie's disease (penis) • Nephrogenic systemic fibrosis (skin) • Progressive massive fibrosis (lungs); a complication of pneumoconiosisRetroperitoneal fibrosis (soft tissue of the retroperitoneum) • Scleroderma/systemic sclerosis (skin, lungs) • Some forms of adhesive capsulitis (shoulder) Fibrosis reversal Historically, fibrosis was considered an irreversible process. However, several recent studies have demonstrated reversal in liver and lung tissue, and in cases of renal, myocardial, and oral-submucosal fibrosis. == References ==
tickerdossier.comtickerdossier.substack.com